The present invention describes methods for synthesizing novel dithiolane
derivatives, ligands with high affinity for the nuclear hormone receptors,
peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) and/or
PPAR.alpha.. Methods for using these compounds in the treatment of
endocrine, skin, cardiovascular, immunological, neurological,
neuropsychiatric, neoplastic and chronic viral diseases of various organs,
including the eye are described. Methods of treating proliferative and
inflammatory diseases, degenerative diseases, and age-related
dysregulations, caused by an hereditary (genetic) condition or an
environmental insult are also provided. In addition, methods are provided
for treating conditions and diseases comprising the step of administering
to a human or an animal in need thereof a therapeutic amount of
pharmacological compositions comprising a pharmaceutically acceptable
carrier, a PPAR.alpha. agonist, and a second agent selected from the
following: a PPAR.gamma. ligand, or an RXR ligand (rexinoid), or a
PPAR.gamma./RXR ligand, effective to reverse, slow, stop, or prevent the
pathological inflammatory or degenerative process.
A invenção atual descreve métodos para synthesizing os derivatives do dithiolane da novela, ligands com afinidade elevada para os receptors nucleares do hormone, receptor-.gamma proliferator-ativado peroxisome. (PPAR.gamma.) e/ou PPAR.alpha.. Os métodos para usar estes compostos no tratamento das doenças viral do endocrine, da pele, as cardiovascular, as immunological, as neurological, as neuropsychiatric, as neoplastic e as crônicas de vários órgãos, including o olho são descritos. Os métodos de tratar doenças proliferative e inflammatory, doenças degenerative, e os dysregulations age-related, causados por uma condição (genetic) hereditary ou por um insulto ambiental são fornecidos também. Além, os métodos são fornecidos para as circunstâncias e as doenças de tratamento que compreendem a etapa da administração a um ser humano ou a um animal na necessidade disso uma quantidade therapeutic de composições pharmacological que compreendem um portador pharmaceutically aceitável, um agonist de PPAR.alpha., e um segundo agente selecionado do seguinte: um ligand de PPAR.gamma., ou um ligand de RXR (rexinoid), ou um ligand de PPAR.gamma./RXR, eficaz inverter, retardam, param, ou impedem o processo inflammatory ou degenerative pathological.
